Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
